Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Furmonertinib”

56 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 56 results

Testing effectiveness (Phase 2)Looking for participantsNCT06728865
What this trial is testing

Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)EGFR Mutation-Positive Lung CancerBrain Metastases+2 more
Li-kun Chen 70
Large-scale testing (Phase 3)Active Not RecruitingNCT05607550
What this trial is testing

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Who this might be right for
Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerEGFR Exon 20 Mutations
ArriVent BioPharma, Inc. 398
Testing effectiveness (Phase 2)UnknownNCT04895930
What this trial is testing

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)Study completedNCT06812871
What this trial is testing

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Sun Yat-sen University 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07365410
What this trial is testing

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Brain MetastasesFurmonertinib+1 more
Tianjin Medical University Cancer Institute and Hospital 60
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Large-scale testing (Phase 3)Looking for participantsNCT06970639
What this trial is testing

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Who this might be right for
NSCLC Patients With Brain Metastasis
Allist Pharmaceuticals, Inc. 380
Not applicableLooking for participantsNCT07348965
What this trial is testing

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Leptomeningeal MetastasisFurmonertinib+1 more
Guangzhou University of Traditional Chinese Medicine 42
Testing effectiveness (Phase 2)Looking for participantsNCT05503667
What this trial is testing

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Who this might be right for
Lung Adenocarcinoma Stage IIILung Adenocarcinoma Stage IVEGFR Gene Mutation
Shanghai Pulmonary Hospital, Shanghai, China 96
Testing effectiveness (Phase 2)Study completedNCT05465343
What this trial is testing

Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

Who this might be right for
FurmonertinibEGFR-mutationNSCLC+1 more
Peking Union Medical College 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06319950
What this trial is testing

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Who this might be right for
Lung Cancer, Nonsmall Cell
Taizhou Hospital 255
Testing effectiveness (Phase 2)Looking for participantsNCT06192849
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Juan LI, MD 20
Testing effectiveness (Phase 2)UnknownNCT05813522
What this trial is testing

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Who this might be right for
Non Small Cell Lung Cancer
First Affiliated Hospital of Zhejiang University 30
Early research (Phase 1)Study completedNCT03926182
What this trial is testing

Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers

Who this might be right for
Healthy Male Volunteers
Allist Pharmaceuticals, Inc. 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04965831
What this trial is testing

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Who this might be right for
Lung Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 40
Large-scale testing (Phase 3)UnknownNCT05209256
What this trial is testing

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Who this might be right for
NSCLC
The First Affiliated Hospital of Henan University of Science and Technology 90
Testing effectiveness (Phase 2)UnknownNCT04970693
What this trial is testing

Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

Who this might be right for
Non-small Cell Lung CancerOligoprogressive
Sun Yat-sen University 64
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07517640
What this trial is testing

Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 45
Testing effectiveness (Phase 2)Looking for participantsNCT05821933
What this trial is testing

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Who this might be right for
NSCLC
RemeGen Co., Ltd. 106
Load More Results